LESER THOMAS DYRMANN,MYLING PETERSEN DORTE,CHRISTENSEN JEFFREY EARL,WELLEJUS ANJA,BROCKMANN ELKE
申请号：
IN201747010367
公开号：
IN201747010367A
申请日:
2017.03.24
申请国别(地区):
IN
年份:
2017
代理人:
摘要：
BifidobacteriumadolescentisThe present invention relates to novel isolated strains of which are capable of i) increasing the trans epithelial electrical resistance (TER) of a Caco 2 cell monolayer after 10h treatment to more than 120% of TER at treatment start ii) inducing secretion of >200 pg/ml of IL 10 and/or iii) inducing an IL 10:IL 12 ratio > 1 when co incubated with human PBMC derived dendritic cells. The strains may have one two or all three of these capabilities. The present invention relates to the use of these novel strains for the in prevention alleviation of symptoms and treatment of diseases or conditions with an underlying impaired intestinal barrier function and pro inflammatory activation of the mucosa. More specifically the present invention relates to se of an isolated strain according to the invention for the prevention alleviation of symptoms or treatment of intestinal inflammatory conditions such as IBD and IBS liver diseases such as NAFLD NASH cirrhosis and alcohol related liver disease metabolic disorders such as metabolic syndrome insulin resistance type 2 diabetes obesity cardiovascular atherosclerosis autoimmune diseases such as celiac disease type 1 diabetes multiple sclerosis and rheumatoid arthritis and mental conditions such as major depressive disorders a mood disorder a cognitive chronic fatigue syndrome and anxiety.
